Fig. 2
BRD9 defines a distinct, non-canonical BAF complex. a Immunoprecipitation (IP)-mass spectrometry using BRD9 or IgG antibody from mouse ESCs. The plot shows the spectral count fold change in BRD9 IP relative to IgG and the corresponding AC test p values, calculated with two technical replicates using PatternLab. In orange are proteins that satisfy FC 2, AC test p < 0.05. b Immunoblotting analysis of fractions after mouse ESC nuclear lysates were subjected to a density sedimentation assay in 10–30% glycerol gradient. LMW and HMW indicate lower and higher molecular weights, respectively. Nonspecific bands are marked with an asterisk. Molecular weights from ladder are indicated. c Immunoprecipitation (IP) experiments from mouse ESC nuclear lysates using antibodies against BRG1, BRD9, and BAF47. Blots developed using chemiluminescence are marked with double asterisks; each IP was taken from a different exposure. d Depletion IP experiment from ESCs using antibodies against BRG1 or BAF155. Each lane shows the remaining proteins after each successive IP, labeled 1 through 4. e IP experiment from ESCs using antibodies against IgG or BRD9, which was incubated in increasing concentration of urea. f Schematic of the esBAF, GBAF, and PBAF complexes in mouse ESCs. Colored in orange, pink, and mustard yellow are subunits that define each individual complex. In green is the enzymatic component, BRG1. Source data are provided as a Source Data file
